Equities
  • Price (EUR)2.54
  • Today's Change-0.058 / -2.23%
  • Shares traded0.00
  • 1 Year change56.50%
  • Beta0.9722
Data delayed at least 15 minutes, as of Sep 24 2020 14:40 BST.
More ▼

Profile data is unavailable for this security.

About the company

PDL BioPharma, Inc. is focused on developing therapeutics and healthcare technologies. Through its subsidiary, LENSAR, Inc., the Company provides medical devices. It is focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System, which is the femtosecond cataract laser built for refractive cataract surgery. LENSAR Laser System offers cataract surgeons automation and customization for their astigmatism treatment planning and other steps of the refractive cataract surgery procedure. It assists surgeons in managing their astigmatism treatment plans for optimal overall visual outcomes.

  • Revenue in USD (TTM)51.81m
  • Net income in USD-85.65m
  • Incorporated1986
  • Employees75.00
  • Location
    PDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
  • Phone+1 (775) 832-8500
  • Fax+1 (775) 832-8501
  • Websitehttp://www.pdl.com
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.